Neurotensin receptor agonists and opioid receptor agonists

Details Neurotensin receptor agonists and opioid receptor agonists Neurotensin receptor agonists and opioid receptor agonists

2010-02-27

2011-11-15

Tate, Christopher R. (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S282000

Reexamination Certificate

active

08058230

ABSTRACT:
This document provides methods and materials for treating pain. For example, this document provides methods that involve administering a neurotensin receptor (NTR) agonist and an opioid receptor agonist to a mammal (e.g., a human). Compositions containing an NTR agonist in combination with an opioid receptor agonist also are provided.

REFERENCES:
patent: 4254107 (1981-03-01), Veber
patent: 4299838 (1981-11-01), Durlach
patent: 4331646 (1982-05-01), Delaage
patent: 4518587 (1985-05-01), Laruelle
patent: 5393740 (1995-02-01), Amagaya
patent: 5578651 (1996-11-01), Lamberts et al.
patent: 5631265 (1997-05-01), Audia
patent: 6046180 (2000-04-01), Jackson
patent: 6214790 (2001-04-01), Richelson
patent: 6765099 (2004-07-01), Richelson
patent: 6921805 (2005-07-01), Richelson
patent: 7098307 (2006-08-01), Richelson
patent: 7671025 (2010-03-01), Barbut et al.
patent: 2002/0187958 (2002-12-01), Horrobin
patent: 2007/0015718 (2007-01-01), Mitchell
patent: 2008/0167388 (2008-07-01), Demopulos
patent: 0 333 071 (1989-09-01), None
patent: WO 96/03400 (1996-02-01), None
patent: WO 96/39162 (1996-12-01), None
patent: WO 97/48400 (1997-12-01), None
Al-Rodhan NR et al., “Structure-antinociceptive activity of neurotensin and some novel analogues in the periaqueductal gray region of the brainstem,” Brain Res. 557: 227-235 (1991).
Bissette G et al., “Hypothermia and intolerance to cold induced by intracisternal administration of the hypothalamic peptide neurotensin,” Nature 262:607-609 (Aug. 12, 1976).
Carraway R and SE Leeman, “The isolation of a new hypotensive peptide, neurotensin, from bovine hypothalami,” J. Biol. Chem. 248: 6854-6861 (Oct. 10, 1973).
Clineschmidt BV and JC McGuffin, “Neurotensin administered intracisternally inhibits responsiveness of mice to noxious stimuli,” Eur. J. Pharmacol. 46: 395-396 (1977).
Cusack B et al., “Pharamacological and biochemical profiles of unique neurotensin 8-13 analogs exhibiting species selectivity, stereoselectivity, and superagonism,” J. Biol. Chem. 270: 18359-18366 (Aug. 4, 1995).
Cusack B et al., “Pharmacological studies on novel neurotensin mimetics: discovery of a pharmacologically unique agent exhibiting concentration-dependent dual effects as antagonist and agonist,” Mol. Pharmacol. 44:1036-1040 (1993).
Cusack B et al., “Effects of a novel neurotensin peptide analog given extracranially on CNS behaviors mediated by apomorphine and haloperidol,” Brain Research 856:48-54 (2000).
Fauq AH et al., “Synthesis of (2S)-2-amino-3-(1H-4-indolyl) propanoic acid, a novel tryptophan analog for structural modification of bioactive peptides,” Tetrahedron: Asymmetry 9:4127-4134 (1998).
Huang W and Hanson GR, “Differential effect of haloperidol on release of neurotensin in extrapyramidal and limbic systems,” Eur. J. Pharmacology 332:15-21 (1997).
Jolicoeur FB et al., “Differential neurobehavioral effects of neurotensin and structural analogues,” Peptides 2:171-175 (1981).
Kitabgi P et al., “Neurotensin binding to extraneural and neural receptors: comparison with biological activity and structure-activity relationships,” Molecular Pharmacology 18:11-19 (1980).
Lambert PD et al., Anatomy and mechanisms of neurotensin-dopamine interactions in the central nervous system, Annals New York Academy of Sci. 757:377-389 (1995).
Li X-M et al., “Neurotensin peptides antagonistically regulate postsynaptic dopamine D2 receptors in rat nucleus accumbens: a receptor binding and microdialysis study,” J. Neural. Transm. 102:125-137 (1995).
Morbeck DE et al., “Analysis of hormone-receptor interaction sites using synthetic peptides: Receptor binding regions of the alpha-subunit of human choriogonadotropin,” In: Methods: A Companion to Methods in Enzymology 5:191-200, Academic Press Inc., New York (1993).
Radke JM et al., “Atypical antipsychotic drugs selectively increase neurotensin efflux in dopamine terminal regions,” Proc. Natl. Acad. Sci. USA 95:11462-11464 (Sep. 15, 1998).
Sarhan S et al., “Comparative antipsychotic profiles of neurotensin and a related systemically active peptide agonist,” Peptides 18(8):1223-1227 (1997).
Snijders R et al., “Neurotensin induces catalepsy in mice,” Neuropharmacology 21: 465-468 (1982).
Troxler von Franz, “Praparative verwendung von mannich-basen von hydroxy-indolen als alkylierungsmittel,” Helvetica Chimica Acta, Volumen 51, Fasciculus 6:1214-1224 (1968).
Tyler BM et al., “In vitro binding and CNS effects of novel neurotensin agonists that cross the blood-brain barrier,” Neuropharmacology 38:1027-1034 (1999).
Tyler BM et al., “Evidence for additional neurotensin receptor subtypes: neurotensin analogs that distinguish between neurotensin-mediated hypothermia and antinociception,” Brain Research 792:246-252 (1998).
Tyler-McMahon et al., “Neurotensin: peptide for the next millennium,” Regulatory Peptides 93:125-136 (2000).
Vincent Jean-Pierre et al., “Neurotensin and neurotensin receptors,” TIPS 20:302-309 (1999).

Affiliated with

Also associated with

Rating

Neurotensin receptor agonists and opioid receptor agonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Neurotensin receptor agonists and opioid receptor agonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Neurotensin receptor agonists and opioid receptor agonists will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4259033